Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.33 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.33 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | FGF1 | P05230 | 1/20 | 0.30 |
| ▸ | VEGFA | P15692 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26549795 | 0.90 | MEN1 (0.33) | KMT2AMEN1DNM1 | |
| SCHEMBL18372007 | 0.90 | MEN1 (0.33) | KMT2AMEN1DNM1 | |
| SCHEMBL16863822 | 0.89 | HDAC3 (0.33) | KMT2AMEN1HDAC3HDAC4HDAC1 | |
| SCHEMBL9887118 | 0.88 | HDAC3 (0.32) | KMT2AHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL19929072 | 0.88 | MEN1 (0.32) | KMT2AMEN1DNM1 | |
| SCHEMBL16750157 | 0.86 | LMNA (0.38) | KMT2AGAAHTT | |
| SCHEMBL14073678 | 0.83 | PRMT3 (0.32) | — | |
| SCHEMBL15479660 | 0.81 | MCL1 (0.41) | KMT2AMEN1GAAHTTNPC1 | |
| SCHEMBL14128720 | 0.79 | MEN1 (0.32) | KMT2AMEN1DNM1 | |
| SCHEMBL13500395 | 0.79 | MEN1 (0.32) | KMT2AMEN1DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180092938-A1 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-04-05 | — | — | US | disclosed |
| US-9833468-B2 | Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9682097-B2 | Oligonucleotide analogues targeting human LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20170051278-A1 | METHODS FOR TREATING PROGEROID LAMINOPATHIES USING OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | SAREPTA THERAPEUTICS, INC. | 2017-02-23 | — | — | US | disclosed |
| US-9394323-B2 | Antisense antiviral compound and method for treating influenza viral infection | SAREPTA THERAPEUTICS, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-9326992-B2 | Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-20160102307-A1 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2016-04-14 | — | — | US | disclosed |
| US-20150368653-A1 | ANTISENSE MODULATION OF NUCLEAR HORMONE RECEPTORS | SAREPTA THERAPEUTICS INC (US) | 2015-12-24 | — | — | US | disclosed |
| US-9066967-B2 | Oligonucleotide analogues targeting human LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-20140303032-A1 | SYSTEMS AND METHODS FOR DETERMINING GENETIC DATA | Roche Sequencing Solutions, Inc. | 2014-10-09 | — | — | US | disclosed |
| US-20140303073-A1 | ANTISENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING INFLUENZA VIRAL INFECTION | SAREPTA THERAPEUTICS, INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-20140296321-A1 | METHODS AND COMPOSITIONS FOR MANIPULATING TRANSLATION OF PROTEIN ISOFORMS FROM ALTERNATIVE INITIATION OF START SITES | SAREPTA THERAPEUTICS, INC. (US) | 2014-10-02 | — | — | US | disclosed |
| US-8697858-B2 | Antisense antiviral compound and method for treating influenza viral infection | SAREPTA THERAPEUTICS, INC. (US) | 2014-04-15 | — | — | US | disclosed |
| US-20140024821-A1 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-20140024698-A1 | METHODS FOR TREATING PROGEROID LAMINOPATHIES USING OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | SAREPTA THERAPEUTICS, INC. (US) | 2014-01-23 | — | — | US | disclosed |
| US-20130230856-A1 | CAPTURE OF TARGET DNA AND RNA BY PROBES COMPRISING INTERCALATOR MOLECULES | QUANTIBACT A/S (DK) | 2013-09-05 | — | — | US | disclosed |
| US-20120095116-A1 | PROBE SET FOR IDENTIFICATION OF NUCLEOTIDE MUTATION, AND METHOD FOR IDENTIFICATION OF NUCLEOTIDE MUTATION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-19 | — | — | US | disclosed |
| US-20110118334-A1 | ANTISENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING INFLUENZA VIRAL INFECTION | AVI BIOPHARMA, INC. (US) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303073-A1 | ANTISENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING INFLUENZA VIRAL INFECTION | UPF1, NSUN2, NUDT21 | KMT2A 2956/4885MEN1 4543/4885GAA 1325/4885 |
| US-20110118334-A1 | ANTISENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING INFLUENZA VIRAL INFECTION | UPF1, NSUN2, NUDT21 | KMT2A 2956/4885MEN1 4543/4885GAA 1325/4885 |
| US-20160102307-A1 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | LMNB2, LMNA, LMNB1 | KMT2A 2457/4885MEN1 817/4885GAA 848/4885 |
| US-20140024698-A1 | METHODS FOR TREATING PROGEROID LAMINOPATHIES USING OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | LMNA, LMNB2, LMNB1 | KMT2A 2685/4885MEN1 1171/4885GAA 275/4885 |
| US-20170051278-A1 | METHODS FOR TREATING PROGEROID LAMINOPATHIES USING OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | LMNA, LMNB2, LMNB1 | KMT2A 2685/4885MEN1 1171/4885GAA 275/4885 |
| US-20180092938-A1 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA | LMNB2, LMNA, LMNB1 | KMT2A 2457/4885MEN1 817/4885GAA 848/4885 |
| US-20120095116-A1 | PROBE SET FOR IDENTIFICATION OF NUCLEOTIDE MUTATION, AND METHOD FOR IDENTIFICATION OF NUCLEOTIDE MUTATION | NT5C3B, UPF1, NUDT21 | KMT2A 3310/4885MEN1 3161/4885GAA 1364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.